Emerging data suggest Retatrutide , a dual activator targeting both GLP-1 and another hormone, may represent a significant advancement for obesity management . Initial patient investigations have indicated substantial losses in abdominal tissue, conceivably outperforming current body composition medications . Despite this, additional study is neede